top of page

The first patented orodispersible film formulation containing riluzole

1,2

In the UK, riluzole remains the only approved disease-modifying drug for ALS.

1,2

1. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918–1929 2. Rilutek (riluzole 50mg tablets) Summary of Product Characteristics

Emylif (12).png
Steps for administration

Steps for administration

Before taking emylif.png

1. Before taking Emylif...

  • Ensure hands and clean and dry

  • Check expiration date and do not use if expired

Open sachet.png

2. Open sachet

  • Fold foil sachet along solid line at top

  • While keeping top of sachet folded over at solid line, tear down at the slit along the arrow on the side of the sachet

Remove film.png

3. Remove film

  • Remove Emylif film from foil sachet

  • Each sachet contains one dose of Emylif

  • Do not fold Emylif film

Place film.png

4. Place film on tongue 

  • Place Emylif film on top of the tongue

  • The film will stick to the tongue and begin to dissolve

5. Close mouth and swallow saliva

  • Close mouth and swallow saliva normally

  • Emylif dissolves within 3 minutes

  • Do not take Emylif with liquids and do not chew, spit or talk while Emylif dissolves

After administeration.png

6. Wash hands

  • After the administration of Emylif, wash your hands

Why use Emylif?

The formulation of riluzole may be adding to the burden of ALS for your patients and their carers.

Emylif_Icon1.png

Ease of administration

  • Administration of a Emylif dose only requires placing the film on the tongue (Emylif SmPC) and could prolong patient autonomy in taking the drug without the use of a carer, thus improving the autonomy and self-esteem of ALS patients

  • Emylif is suitable at all stages of ALS, which enables patients to maintain the same treatment throughout the course of the disease

Emylif_Icon2.png

Consistency and accuracy of dosing

  • The practice of crushing of tablets has been shown to result in drug losses (Thong et al, 2018) and has an unknown impact on efficacy

  • Emylif is placed on the tongue to dissolve, does not need to be crushed and does not require the use of a syringe to measure the dose for administration

Adherance and compliance to treatment

  • By improving ease of drug delivery, Emylif may improve adherence to riluzole treatment due to minimal preparation and administration time (patient and/or carer) compared to solution or crushed tablet administration

Benefits of Emylif

References

Emylif (riluzole). Summary of Product Characteristics

Thong MY, PLoS ONE 13(3): e0193683. https://doi.org/10.1371/ journal.pone.0193683

References
Adverse event reporting

GB_ROF_030

April 2023

bottom of page